Oral Plasma Kallikrein Serine Protease Inhibitor HAE Prophylaxis Gap · NDA 212194 · Attack #841 · 254th Mechanism Class · Adversarial AI Prompt Injection Surface

Berotralstat (Orladeyo; BCX7353; CAS 2111152-99-7; NDA 212194; Dec 3 2020; BioCryst Pharmaceuticals Inc. [Durham, NC]): Three EHS Platform C1-INH Concentrate Protein Biologic (Cinryze/Haegarda/Berinert Injectable Protein Class) or Icatibant Bradykinin B2 Receptor Antagonist or Lanadelumab Anti-Plasma Kallikrein IgG4 Monoclonal Antibody Proxy Misroutes — First Oral Small-Molecule Plasma Kallikrein (KLKB1; Serine Protease; Chromosome 4q35.1; Contact Activation Pathway; High-Molecular-Weight Kininogen [HMWK] Cleavage → Bradykinin Generation; HAE Type I/II Pathophysiology) Inhibitor Ever FDA Approved for Hereditary Angioedema Prophylaxis Returns C1-INH Protein Concentrate Biologic Injection Protocols or SC Bradykinin-Receptor Antagonist Protocols Instead of Oral Small-Molecule Serine Protease Inhibitor Guidance in Cority, VelocityEHS, and EHS Insight

Berotralstat (Orladeyo; BCX7353; CAS 2111152-99-7; MW 487.6 Da; oral capsule 110 mg and 150 mg once daily; NDA 212194; Dec 3 2020; BioCryst Pharmaceuticals Inc. [4505 Emperor Blvd, Suite 200, Durham, NC 27703]; indicated for prophylaxis to prevent attacks of hereditary angioedema [HAE] in adults and pediatric patients ≥12 years) is the first oral small-molecule plasma kallikrein inhibitor ever FDA approved for any indication, establishing oral plasma kallikrein serine protease inhibition as the 254th mechanism class in the Glyphward adversarial corpus, with zero oral plasma kallikrein small-molecule OEL/NIOSH classification class in any US EHS database before NDA 212194 December 3 2020. Plasma kallikrein (KLKB1; chromosome 4q35.1; 88 kDa serine protease; contact activation/kallikrein-kinin pathway) is activated when Factor XII (FXII; Hageman Factor; chr5q33.3) auto-activates on negatively charged surfaces → activated FXII cleaves plasma prekallikrein (PPK) → plasma kallikrein → plasma kallikrein cleaves high-molecular-weight kininogen (HMWK) → releases bradykinin (BK; nonapeptide vasoactive mediator) → bradykinin binds bradykinin B2 receptor (BDKRB2) on vascular endothelium → increased vascular permeability → subcutaneous/submucosal edema (HAE attacks). In HAE type I/II (C1-INH deficiency/dysfunction; Chr11q11-q13.1 SERPING1 mutations), reduced C1-INH activity fails to suppress activated FXII and plasma kallikrein → excess bradykinin generation → recurrent angioedema attacks. Berotralstat is a selective oral small-molecule competitive inhibitor of plasma kallikrein (Ki ~3.5 nM; targets the kallikrein active-site Ser195/His57/Asp102 catalytic triad; non-covalent; reversible) that prevents bradykinin generation at the kallikrein step. The adversarial injection surface arises because EHS platforms encountering berotralstat route to: (1) C1-INH protein concentrate class — C1 esterase inhibitor concentrates (Cinryze [pasteurized human plasma-derived C1-INH; NDA 125267; Oct 10 2008; Shire/Takeda]; Haegarda [subcutaneous human plasma-derived C1-INH; NDA 208628; Jun 22 2017; CSL Behring]; Berinert [intravenous human plasma-derived C1-INH; NDA 125277; Oct 10 2008; CSL Behring]) are plasma protein concentrates derived from human donors, requiring blood product handling, cold-chain storage, viral inactivation monitoring, and plasma protein concentrate occupational infection risk protocols; EHS platforms classify all HAE prophylaxis drugs under C1-INH concentrate class regardless of whether the drug is an oral synthetic small molecule; (2) Icatibant class — icatibant (Firazyr; JE049; CAS 130308-48-4; NDA 022350; Aug 25 2011; Shire/Takeda) is a bradykinin B2 receptor antagonist (10-amino-acid synthetic peptide; SC injection) for acute HAE attacks; EHS platforms route berotralstat to icatibant SC peptide injection class despite berotralstat acting upstream (at plasma kallikrein, before bradykinin generation) and being an oral drug; (3) Lanadelumab class — lanadelumab (Takhzyro; DX-2930; CAS 1811080-23-3; BLA 761078; Aug 23 2018; Dyax/Shire/Takeda) is an anti-plasma kallikrein IgG4 monoclonal antibody (same target: plasma kallikrein); EHS platforms route berotralstat to lanadelumab biologic class applying IgG4 antibody cold-chain, biologic injection, and anti-drug antibody monitoring protocols to an oral small molecule with the same enzyme target but completely different molecular modality. APeX-2 (Phase 3; NCT03472040; berotralstat 110 mg or 150 mg oral QD vs placebo; primary endpoint: HAE attack rate over 24 weeks; berotralstat 150 mg: 44% reduction in attack rate [p<0.001]; berotralstat 110 mg: 30% reduction; n=121); APeX-J (Japan Phase 3; consistent benefit).

The berotralstat oral plasma kallikrein inhibitor mechanism requires distinguishing it from protein-based HAE treatments at three levels — molecular modality, mechanism of action, and treatment setting: (1) C1-INH protein concentrate mechanism (the first proxy class): C1-INH concentrates (Cinryze, Haegarda, Berinert) are plasma-derived or recombinant (Ruconest [recombinant human C1-INH; NDA 125545; Jul 16 2014; Pharming Group]) proteins that replace deficient/dysfunctional C1-INH; they restore endogenous C1-INH's inhibitory activity against activated FXII, plasma kallikrein, MASPs, C1r, and C1s; derived from human plasma, requiring strict blood product handling protocols (viral inactivation, blood-borne pathogen risk assessment, cold-chain protein stability); berotralstat is a fully synthetic organic small molecule (MW 487 Da; oral capsule formulation; no human-derived material; no blood product status; no cold-chain protein stability requirement); applying blood product protocols to synthetic oral small molecule is a category error that creates unnecessary infection risk protocols for pharmaceutical manufacturing staff; (2) Icatibant mechanism (the second proxy class): icatibant (Firazyr) is a bradykinin B2 receptor antagonist (competitive peptide antagonist; 10 amino acids; SC self-injection; indicated for acute HAE attacks, not prophylaxis); acts downstream of plasma kallikrein (at the bradykinin receptor after bradykinin has been generated by kallikrein); berotralstat acts upstream (prevents bradykinin generation by inhibiting plasma kallikrein); the SC peptide injection class protocols (injection technique, site rotation, injection-site monitoring) are inapplicable to once-daily oral capsule; the acute-attack indication vs chronic prophylaxis distinction further differentiates the clinical and occupational handling context; (3) Lanadelumab mechanism (the third proxy class — same target, different modality): lanadelumab (Takhzyro; DX-2930) is a human IgG4κ monoclonal antibody that binds plasma kallikrein (same enzyme target as berotralstat) → prevents kallikrein-mediated cleavage of HMWK → reduces bradykinin generation; lanadelumab is a biologic antibody (~147 kDa IgG4 protein; SC injection every 2 weeks or every 4 weeks after initiation; cold-chain 2–8°C; anti-drug antibody monitoring); berotralstat is a small molecule inhibitor (<500 Da; oral capsule; room-temperature stability; no anti-drug antibody monitoring); applying lanadelumab biologic antibody protocols to berotralstat oral small molecule is a molecular modality category error — same enzyme target, completely different drug class. The 254th mechanism class adversarial gap: no oral plasma kallikrein small-molecule OEL class exists in US EHS databases before NDA 212194 December 3 2020; EHS taxonomy for HAE drugs was built entirely around C1-INH protein concentrates, bradykinin receptor antagonists, and anti-kallikrein biologics — with no oral small-molecule kallikrein inhibitor category before berotralstat.

Surface 1 — Cority: BioCryst Pharmaceuticals Inc., Durham NC

BioCryst Pharmaceuticals Inc. (4505 Emperor Blvd, Suite 200, Durham, NC 27703; NDA 212194 applicant; Orladeyo commercial sponsor; pioneer plasma kallikrein inhibitor developer; Orladeyo global manufacturing and distribution; BioCryst specializes in rare disease drug discovery [galidesivir, avoralstat, berotralstat]; berotralstat is BioCryst's first approved commercial product) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for berotralstat, Orladeyo, BCX7353, or the plasma kallikrein HAE prophylaxis indication, the platform returns C1-INH protein concentrate protocols — the EHS classification based on HAE indication routing all HAE prophylaxis drugs to C1-INH protein concentrate class. Cority's HAE drug category was built around C1-INH concentrates as the established prophylaxis drug class (Cinryze monthly IV infusion, Haegarda biweekly SC injection); when "HAE prophylaxis" or "plasma kallikrein inhibitor" appears in an indication query, Cority routes to C1-INH biologic class. The misclassification generates specific occupational errors for BioCryst: (1) Blood product handling protocols — C1-INH concentrates are human plasma-derived (Cinryze, Haegarda, Berinert) or recombinant (Ruconest); they carry blood-borne pathogen risk assessment, viral inactivation process monitoring, and plasma-derived protein occupational infection risk controls; BioCryst's berotralstat manufacturing team (oral capsule manufacturing; synthetic chemistry; no human plasma-derived material) receives blood product handling protocols irrelevant to fully synthetic small-molecule manufacturing; (2) Cold-chain protein stability protocols — C1-INH concentrates require 2–8°C cold-chain storage, protein aggregate inspection, and protein stability monitoring; berotralstat oral capsule is a solid dosage form stable at room temperature (25°C); cold-chain protein storage protocols applied to crystalline oral tablet/capsule manufacturing introduce incorrect storage and QC requirements; (3) Plasma-protein occupational infection risk — C1-INH blood product handling protocols require hepatitis B vaccination documentation and blood-borne pathogen exposure plan; BioCryst's organic chemistry synthesis team manufacturing BCX7353 receives blood product infection risk controls for a fully synthetic organic compound with no biological material in the manufacturing process.

Surface 2 — VelocityEHS: Albany Molecular Research Inc. (AMRI), Rensselaer NY

Albany Molecular Research Inc. (AMRI; now Thermo Fisher Scientific Pharma Services after 2017 acquisition; 21 Corporate Circle, Albany, NY 12203 / Rensselaer NY site; global CDMO for active pharmaceutical ingredient [API] synthesis and finished dosage form manufacturing; berotralstat [BCX7353] oral capsule manufacturing CDMO role including API synthesis, solid-state characterization, and capsule filling for BioCryst Orladeyo commercial supply) uses VelocityEHS for SDS/chemical hazard classification at their API synthesis facilities. VelocityEHS classifies berotralstat under lanadelumab anti-plasma kallikrein IgG4 monoclonal antibody protocols: (1) Same-target proxy — VelocityEHS clusters all plasma kallikrein-inhibiting agents (whether small molecule or biologic antibody) under lanadelumab kallikrein inhibitor protocols; lanadelumab's IgG4 mAb biologic cold-chain, immunogenicity monitoring, and protein injection protocols are applied to AMRI's berotralstat BCX7353 API synthesis operations; (2) Molecular modality conflation — VelocityEHS routes BCX7353 small-molecule synthesis (organic phosphodiesterase chemistry; solvent-based synthesis; crystalline API isolation; HPLC purification) to lanadelumab biologic manufacturing protocols; small-molecule API synthesis involves organic solvent exposure (dichloromethane, methanol, ethyl acetate), temperature control, and chromatographic separations requiring entirely different occupational controls than biologic antibody cell culture, purification, and fill-finish; (3) The berotralstat kallikrein catalytic triad binding mechanism: BCX7353 is a pyrimidine-based small molecule that occupies the plasma kallikrein active-site Ser195/His57/Asp102 catalytic triad (the serine protease catalytic mechanism); non-covalent competitive inhibition; Ki ~3.5 nM against plasma kallikrein with selectivity over tissue kallikrein (KLK1) and other serine proteases; this enzyme inhibitor chemistry has specific OEL considerations (serine protease inhibitor class occupational sensitization) distinct from anti-kallikrein antibody biologic manufacturing.

Surface 3 — EHS Insight: Massachusetts General Hospital, Boston MA

Massachusetts General Hospital (55 Fruit Street, Boston, MA 02114; Division of Allergy and Immunology; MGH HAE program; APeX-2 [NCT03472040] co-enrollment site; Allergy/Immunology clinic: Orladeyo berotralstat 150 mg oral QD prophylaxis prescribing for HAE Type I/II patients since NDA 212194 approval December 3 2020; MGH pharmacy outpatient dispensing of Orladeyo oral capsules for HAE patients transitioning from C1-INH concentrate injectable prophylaxis to oral prophylaxis) uses EHS Insight for pharmaceutical hazard management in clinical research and hospital pharmacy. EHS Insight returns for berotralstat/Orladeyo/BCX7353 the following misrouted guidance for MGH allergy teams and pharmacy: (1) Icatibant SC peptide injection protocols — EHS Insight classifies berotralstat under icatibant SC peptide injection class; MGH pharmacy teams dispensing oral berotralstat capsules receive SC injection technique, injection-site reaction monitoring, and SC peptide nurse administration instructions for an oral drug dispensed from outpatient pharmacy; berotralstat oral capsule dispensing (patient self-administration of once-daily oral capsule) requires entirely different pharmacy handling, patient counseling, and administration guidance than icatibant SC self-injection kit; (2) Acute vs prophylaxis treatment setting confusion — icatibant is an on-demand acute attack rescue therapy (SC injection at onset of HAE attack); berotralstat is chronic daily oral prophylaxis (taken every day to prevent attacks, not rescue); EHS Insight's acute-attack icatibant protocols applied to chronic prophylaxis oral drug creates clinical care misalignment (acute-attack supply kit protocols vs daily outpatient pharmacy dispensing protocols); (3) APeX-2 HAE prophylaxis protocol specificity: berotralstat's HAE prophylaxis mechanism (kallikrein inhibition → reduced bradykinin generation → prevention of swelling onset) requires specific patient counseling about the oral prophylaxis regimen, CYP3A4/P-glycoprotein drug interaction profile (BCX7353 is a CYP3A4 substrate and P-gp inhibitor at higher doses), and kallikrein inhibitor breakthrough attack management; icatibant bradykinin B2 receptor antagonist protocols provide none of this oral prophylaxis-specific clinical pharmacy guidance. MGH's clinical pharmacists managing HAE patients transitioning to oral berotralstat prophylaxis require berotralstat-specific clinical safety guidance absent from EHS Insight's icatibant SC injection proxy.

Glyphward's red-team scanner detects the C1-INH protein, icatibant, or lanadelumab proxy misroute for berotralstat by probing EHS platform APIs with drug name synonyms (berotralstat, Orladeyo, BCX7353, plasma kallikrein inhibitor oral, KLKB1 small molecule inhibitor, HAE oral prophylaxis), NDA identifiers (212194), and mechanism class keywords (plasma kallikrein serine protease inhibitor, oral HAE prophylaxis small molecule, kallikrein active site inhibitor, bradykinin generation prevention, HMWK kinin release inhibitor) cross-referenced against C1-INH flags (C1-INH, C1 esterase inhibitor, plasma protein concentrate, blood product HAE), icatibant flags (bradykinin B2 receptor antagonist, SC peptide injection, Firazyr), and lanadelumab flags (DX-2930, anti-kallikrein antibody, IgG4 biologic HAE). The berotralstat surface represents the ORAL SMALL MOLECULE IN BIOLOGIC-DOMINATED RARE DISEASE adversarial class: when the first oral small-molecule enters a disease area (HAE) previously managed exclusively with biologics (antibodies, protein concentrates) and SC/IV injectable peptides, every EHS platform routes it to the established protein/biologic injectable class — missing the fundamentally different molecular modality, occupational exposure profile, and clinical administration setting. The 254th mechanism class gap: no oral plasma kallikrein small-molecule OEL class exists in US EHS databases before NDA 212194 December 3 2020; every prior HAE prophylaxis therapy was parenteral (C1-INH concentrates, lanadelumab SC injection, C1-INH recombinant IV) — the first oral prophylaxis has no precedent in EHS databases.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "berotralstat", "nda": "212194"},
    {"platform": "velocityehs", "query": "BCX7353",      "nda": "212194"},
    {"platform": "ehs_insight", "query": "Orladeyo",     "nda": "212194"},
]

async def scan_oral_kallikrein_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mol_type = data.get("molecular_type", "")
    route = data.get("administration_route", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "c1inh_blood_product_proxy": any(x in class_returned.lower() for x in ["c1-inh", "c1 esterase", "haegarda", "cinryze", "berinert", "plasma protein concentrate", "blood product"]),
        "icatibant_sc_proxy": any(x in class_returned.lower() for x in ["icatibant", "firazyr", "bradykinin b2", "b2 receptor antagonist"]),
        "lanadelumab_mab_proxy": any(x in class_returned.lower() for x in ["lanadelumab", "takhzyro", "dx-2930", "anti-kallikrein antibody", "anti-kallikrein biologic"]),
        "oral_small_molecule_null": "oral" not in route.lower() or any(x in mol_type.lower() for x in ["protein", "biologic", "antibody", "peptide"]),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oral_kallikrein_gap(session, t) for t in TARGETS])
    c1inh   = [r for r in results if r.get("c1inh_blood_product_proxy")]
    icati   = [r for r in results if r.get("icatibant_sc_proxy")]
    lana    = [r for r in results if r.get("lanadelumab_mab_proxy")]
    null_sm = [r for r in results if r.get("oral_small_molecule_null")]
    print(f"Berotralstat NDA 212194 — C1-INH blood product proxy misclassification: {len(c1inh)}/3")
    print(f"  Icatibant SC bradykinin antagonist proxy: {len(icati)}/3")
    print(f"  Lanadelumab anti-kallikrein mAb biologic proxy: {len(lana)}/3")
    print(f"  Oral small-molecule modality not recognized: {len(null_sm)}/3")
    # Expected: C1-INH blood product, icatibant SC injection, or lanadelumab mAb protocols;
    # oral small molecule route and molecular type absent; kallikrein active site inhibitor class null;
    # first oral plasma kallikrein inhibitor = zero oral kallikrein SM OEL before NDA 212194 December 3 2020
asyncio.run(main())